Digital PCR Market Forecasts to 2028 – Global Analysis By Product (Instruments, Reagents & Consumables and Other Products), Technology (Droplet Digital PCR, Chip-based Digital PCR and Other Technologies), Indication (Oncology, Infectious Diseases and Othe

Digital PCR Market Forecasts to 2028 – Global Analysis By Product (Instruments, Reagents & Consumables and Other Products), Technology (Droplet Digital PCR, Chip-based Digital PCR and Other Technologies), Indication (Oncology, Infectious Diseases and Other Indications), Application (Oncology Testing, Blood Screening and Other Applications), End User and Geography

According to Stratistics MRC, the Global Digital PCR Market is accounted for $539.73 million in 2022 and is expected to reach $2149.48 million by 2028 growing at a CAGR of 25.9% during the forecast period. The digital polymerase chain reaction (dPCR) is a new technique for quantifying nucleic acids that provides a sensitive and reproducible means to estimate the concentration of DNA or RNA in a sample. Research (basic and applied), clinical diagnostics, forensics, and other sectors all show great promise for dPCR. Applications for dPCR systems include copy number variation, uncommon sequence detection, mutation detection, miRNA analysis, gene expression analysis, and next-generation sequencing sample quantification.

According to the GLOBOCAN report, in 2020, around 19.29 million people in the world are affected by cancer. According to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, in 2021, around 537 million adults all over the world were found to have diabetes; with the numbers projected to grow to 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

Increasing use of biomarkers profiling for disease diagnostics

Nucleic acids (including DNA and micro RNA or mRNA), which may be found and measured in bodily fluids and tissues, are examples of distinctive molecules known as biomarkers or genomic markers. Through the process of molecular profiling at the epigenetic, genetic, and protein levels, a biomarker can be a dependable, precise source for determining the nature of a disease and therapeutic response. Currently, biomarker analysis is employed in diagnostic testing methods, therapeutic efficacy monitoring, and drug development. The isolated sample's genetic material is detected and measured using qPCR and dPCR technology in the biomarker analysis process. With more public and private organisations concentrating on R&D into novel techniques for monitoring disease progression and developing personalised medicines and treatment options, biomarker analysis procedures have grown in significance in the clinical diagnosis and prognosis of diseases over the past ten years.

Restraint:

High Cost of Systems

Digital gadgets have many useful applications, but they also have some drawbacks that may prevent widespread market acceptance. Its acceptance may be constrained by some issues, namely the higher price of these digital gadgets in comparison to alternative options. Multiple alternative possibilities are created as a result of this element in the market. For absolute quantification, counting PCR might be used instead of digital polymerase chain reaction. Gene expressions, copy number variation, and viral load are all quantified. This alternative is anticipated to restrain the market's expansion of these digital devices.

Opportunity:

Several Benefits of dPCR Over Real-time Polymerase

Digital polymerase chain reaction aids in delivering a comprehensive measure of the target nucleic acid molecules as opposed to the relative measure obtained from real-time instruments. Because of the reproducibility, sensitivity, and precision provided by this absolute DNA quantification, researchers are also able to properly assess minor mutations and quantify smaller differences. Due to the numerous types of genomes present in the virus and the extremely low template concentration present in the sample, real-time devices chain reaction is not a preferred technique for detecting various parasitic infectious diseases such as malaria and COVID-19, despite its widespread application. Digital droplet technologies get beyond these problems and produce precise results with improved group comparisons. These elements are therefore accelerating the market's expansion.

Threat:

Lack of technical skills

A typical dPCR method has a number of technical restrictions, including the measurement of the signal during the exponential phase of the PCR reaction, the requirement for assay procedure optimization and validation, difficulties in target detection caused by reaction inhibitors, and the inability to detect the target molecules due to the poor quality of the nucleotide template. Additionally, the usage of carcinogenic chemicals, chemical attachment of the reagent to dsDNA, and inability to measure DNA quality (AluQuant) are some of the operational constraints of qPCR reagents that have a direct impact on their use in genomic research.

Covid-19 Impact

The market grew significantly in 2020 as a result of COVID-19's effects. This is explained by the fact that the virus has spread widely, raising the need for efficient diagnostics to stop its transmission. The market for digital PCR in the world expanded tremendously. The demand for the devices was fuelled by the reallocation of healthcare funds for COVID-19 therapy, which led to an increase in the number of persons seeking a COVID-19 diagnosis and the use of the device in diagnostic centres and research facilities. The considerable growth of COVID-19 testing in high-burden nations worldwide also contributed to the favourable outcome.

The chip-based digital PCR segment is expected to be the largest during the forecast period

The chip-based digital PCR segment is estimated to have a lucrative growth, due to chip-based digital PCR method carries out rtPCR on a huge scale in nanoliter amounts by utilising silicon chips with thousands of interweaving valves and channels. With the same number of assays, the chip can test up to 48 or 96 samples at once, yielding numerous findings from a single response. Chip-based digital PCR is gaining popularity daily due to its decreased risk of cross-contamination and consistent droplet flow. In the future, additional diseases are probably going to be diagnosed with new technologies of this kind

The diagnostics centers segment is expected to have the highest CAGR during the forecast period

The diagnostics centers segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the expanding use of these digital devices for the diagnosis of various sorts of these diseases and the rising prevalence of infectious diseases are both responsible for the segment's growth. Additionally, numerous market participants boosted their focus on creating and marketing COVID-19 diagnostics kits as a result of the COVID-19 outbreak.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its well-established healthcare sector, the presence of top molecular diagnostics firms that invest in the release of new products, and the rise in the proportion of patients utilising personalised medicines. Because there were more elderly individuals, more infectious diseases were being identified, and there were improved healthcare facilities, the digital PCR market in North America expanded. With all of this, the region is anticipated to grow profitably during the projection period.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period; due to it is a major player in the creation and research of pharmaceuticals. Innovative approaches like targeted therapy and personalised precision medicine are being created by merging technology that requires genetic analysis. Because of the substantial institutional funding that Europe offers for R&D, the calibre of research has increased. Due to the high prevalence of diseases in the area and the use of microarray, PCR, and other genomic and proteomic techniques, there has been an increase in the use of molecular diagnostics.

Key players in the market

Some of the key players profiled in the Digital PCR Market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., JN Medsys, QIAGEN, Stilla, Sysmex Corporation, Standard BioTools Inc., Precigenome LLC., Fluidigm Corp., Formulatrix, Inc., Avance Bioscience, Merck KGAA, Agilent Technologies, Inc., BioMérieux, Takara Bio Inc., Beckman Coulter, Inc., General Electric, Roche Sequencing, PerkinElmer Inc. and Siemens

Key Developments:

In April 2022, Stilla and Promega Corporation announced their co-marketing agreement that combined sample preparation with the latest Maxwell systems and digital polymerase chain reaction on the six-color Naica system. This collaboration strengthened both companies’ product portfolio.

In March 2022, Stilla announced its partnership with 12 distributors across the EMEA region. With this partnership, the company expanded its presence in the EMEA region.

In September 2021, Thermo Fisher Scientific Inc. announced the launch of Applied Biosystems Quant Studio Absolute Q a digital system.

In June 2020, Stilla announced the launch of the world’s first six-color digital polymerase chain reaction instrument.

In May 2020, Stilla announced the availability of its digital polymerase chain reaction solution, the Naica system. The product can reliably detect the SARS-CoV-2 virus and measure its viral load in all research centers and hospitals involved in the fight against COVID-19.

Products Covered:
• Instruments
• Reagents & Consumables
• Software and Services
• Digital PCR Equipment
• Other Products

Technologies Covered:
• Droplet Digital PCR
• Chip-based Digital PCR
• Beaming Digital PCR
• Other Technologies

Indications Covered:
• Oncology
• Infectious Diseases
• Genetic Disorders
• Other Indications

Applications Covered:
• Oncology Testing
• Blood Screening
• Transplant Diagnostics
• Research
• Other Applications

End Users Covered:
• Hospitals & Clinics
• Academic & Research Organizations
• Diagnostic Centers
• Pharmaceutical & Biotechnology Industries
• Forensic Laboratories
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements